← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Profectus Biosciences, Inc.
Baltimore, MD
$64,287,117
Total funding
30
Grants
Funding over time
peak $13.9M · FY2005–20$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$62,978,424 · 28
DOD$1,308,693 · 2
By mechanism
N01$27,274,795 · 5
R01$16,758,733 · 4
R44$15,544,922 · 7
R43$2,635,261 · 10
—$1,308,693 · 2
R56$625,704 · 1
Investigators at Profectus Biosciences, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
THERAPEUTIC IMMUNIZATION AGAINST HIV WITH ADJUVANT-ENHANCED DNA AND MULTI-EPITOP$12,110,276
N01 · FY2009 · AI
Advanced Development of a Multivalent Vaccine Candidate for Filovirus and Lassa Fever$6,964,520
N01 · FY2017 · AI
STUDIES REVISED AND DIRECTED AT IN-VITRO AND IN-VIVO CHARACTERIZATION OF AN ATTENUATED MONOVALENT MATERIALS$3,570,155
· FY2015 · Department of the Army
HIV-1 VACCINE CANDIDATES DELIVERED BY VSV VECTORS$2,740,852
N01 · FY2010 · AI
HIV-1 VACCINE CANDIDATES DELIVERED BY VSV VECTORS$1,792,234
N01 · FY2009 · AI
Development of sG as a human vaccine against Nipah/Hendra$1,306,446
R01 · FY2012 · AI
THERAPEUTIC IMMUNIZATION AGAINST HIV WITH ADJUVANT-ENHANCED DNA AND MULTI-EPITOP$1,306,067
N01 · FY2012 · AI
Advanced Development of a Multivalent Vaccine Candidate for Filovirus and Lassa Fever$1,274,067
N01 · FY2019 · AI
rVSV Vectored Vaccine to Protect Against Ebola and Marburg Viruses$1,208,817
R01 · FY2016 · AI
Preclinical Development of m102.4, a Human Anti-Hendra and Nipah Antibody$1,182,666
R01 · FY2014 · AI
Development of sG as a human vaccine against Nipah/Hendra$1,129,038
R01 · FY2016 · AI
rVSV Vectored Vaccine to Protect Against Ebola and Marburg Viruses$1,122,164
R01 · FY2013 · AI
rVSV Vectored Vaccine to Protect Against Ebola and Marburg Viruses$1,120,171
R01 · FY2012 · AI
Preclinical Development of m102.4, a Human Anti-Hendra and Nipah Antibody$1,097,778
R01 · FY2012 · AI
Preclinical Development of m102.4, a Human Anti-Hendra and Nipah Antibody$1,086,738
R01 · FY2011 · AI
Preclinical Development of m102.4, a Human Anti-Hendra and Nipah Antibody$1,039,531
R01 · FY2013 · AI
Development of sG as a human vaccine against Nipah/Hendra$1,035,051
R01 · FY2015 · AI
An HIV Vaccine Strategy Based on Priming with rVSV Expressing FLSC$1,000,000
R44 · FY2016 · AI
An HIV Vaccine Strategy Based on Priming with rVSV Expressing FLSC$1,000,000
R44 · FY2015 · AI
Optimization of a DNA Subunit Regimen for an HIV Vaccine$999,999
R44 · FY2014 · AI